Advancements and Applications of 3DP Printing in Pharmaceutical Development and Biomedical Sciences

Three-dimensional printing (3DP) is revolutionizing pharmaceutical sciences and biomedical applications by offering unprecedented precision, efficiency, and personalization in drug formulation and medical device manufacturing. It enables the production of tailored drug dosage forms with controlled release profiles, making it highly suitable for treating complex diseases such as epilepsy, cancer, and cardiovascular disorders. 3DP also facilitates the creation of polypills, enhancing therapeutic compliance and reducing medication burden in polypharmacy cases. In the biomedical field, 3DP supports the fabrication of patient-specific prosthetics, implantable devices, and bioprinted tissues and organs, thereby improving clinical outcomes. Innovations such as four-dimensional (4D) printing have introduced smart biomaterials that respond to physiological stimuli, significantly advancing drug delivery systems and tissue engineering applications. Moreover, the integration of artificial intelligence (AI) and machine learning with 3DP is paving the way for precision medicine by enabling predictive modeling for drug formulation, streamlining clinical development, and optimizing production parameters. However, the widespread adoption of 3DP in healthcare faces several challenges. Regulatory concerns remain a major hurdle, as existing frameworks are not fully equipped to assess the safety, reproducibility, and quality control of 3D-printed pharmaceuticals. Each formulation often requires individual validation, posing complexities in approval pathways. In addition, biocompatibility issues associated with printing materials—such as thermal degradation, residual solvents, and potential toxicity—demand thorough evaluation to ensure patient safety. Despite these obstacles, ongoing research, regulatory advancements, and interdisciplinary collaboration continue to accelerate progress. Ultimately, 3DP holds immense promise in transforming personalized medicine, decentralized drug manufacturing, and regenerative therapies—ushering in a new era of effective, accessible, and patient-centric treatment strategies.